Atualizações em câncer de ovário e inibidores da PARP

Dra. Maria Del Pilar, oncologista clínica do Instituto do Câncer do Estado de São Paulo (ICESP) e da Rede D´Or – Onco Star, destacou e comentou três estudos importantes para o tratamento de pacientes portadoras de câncer de ovário de alto grau e que receberam inibidores de PARP, principalmente o olaparibe.

Os trabalhos SOLO2, PAOLA-1 e LIGHT foram apresentados durante o ASCO 2020 Virtual Annual Meeting.

Se preferir ouça nosso Podcast:

Referências:
Patterns of progression and subsequent management of patients with BRCA1/2 mutated
platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus
placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). (abstract 6070)
https://meetinglibrary.asco.org/record/187230/abstract

Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in
patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by
BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. (6039 Poster Session)
https://meetinglibrary.asco.org/record/185457/abstract

Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC)
by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II
LIGHT study.(abstract 6013)
https://meetinglibrary.asco.org/record/185447/abstract